# Regorafenib

## Stivarga 40mg (28#/Bot)

##### 臨採

| 藥品代碼   | OSTV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Colorectal cancer: Treatment of patients with metastatic colorectal cancer (mCRC) who have previously received the following therapies， including fluoropyrimidine-， oxaliplatin-， irinotecan-based chemotherapy， and anti-vascular endothelial growth factor (anti-VEGF) therapy; If KRAS is a wild type， the patient needs to have received anti-epidermal growth factor receptor (anti-EGFR) therapy. Gastrointestinal stromal tumors: Treatment of locally advanced， unresectable or metastatic gastrointestinal stromal tumors in patients who have previously received imatinib mesylate and sunitinib malate. Hepatocellular carcinoma: Treatment of hepatocellular carcinoma (HCC) patients who have received sorafenib treatment. |
| 用法用量   | 160 mg (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.Take Stivarga at the same time each day. Swallow tablet whole with a low-fat breakfast that contains less than 30% fat. Examples of a low-fat breakfast include 2 slices of white toast with 1 tablespoon of low-fat margarine and 1 tablespoon of jelly， and 8 ounces of skim milk (319 calories and 8.2 g fat); or 1 cup of cereal， 8 ounces of skim milk， 1 slice of toast with jam， apple juice， and 1 cup of coffee or tea (520 calories and 2 g fat).                                                                                                           |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 禁忌       | Hypersensitivity to regorafenib， any component of the formulation， or sorafenib.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 副作用     | Hypertension， Fatigue， dysphonia， pain， fever， headache， Palmar-plantar erythrodysesthesia， rash， alopecia， Hypocalcemia， hypophosphatemia， hyponatremia， hypokalemia， hypothyroidism， Appetite decreased， lipase increased， diarrhea， mucositis， weight loss， amylase increased， nausea， vomiting， Anemia， lymphopenia， thrombocytopenia， INR increased， hemorrhage， neutropenia， AST increased， ALT increased， hyperbilirubinemia， Stiffness， Proteinuria， Infection.                                                                                                                                                                                                                                         |
| 孕期建議   | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期建議 | No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

